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Abstract
The large chondroitin sulphated proteoglycan aggrecan (ACAN) is the most abundant non-collagenous protein in
cartilage and is essential for its structure and function. Mutations in ACAN result in a broad phenotypic spectrum
of non-lethal skeletal dysplasias including spondyloepimetaphyseal dysplasia, spondyloepiphyseal dysplasia, familial
osteochondritis dissecans and various undefined short stature syndromes associated with accelerated bone maturation.
However, very little is currently known about the disease pathways that underlie these aggrecanopathies, although
they are likely to be a combination of haploinsufficiency and dominant-negative (neomorphic) mechanisms. This
review discusses the known human and animal aggrecanopathies in the context of clinical presentation and
potential disease mechanisms.
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Background
Long bones grow by a process of endochondral ossifica-
tion and disruptions to this intricate and highly coordi-
nated process result in a diverse group of genetic
skeletal diseases (GSDs). GSDs are a clinically and genet-
ically heterogeneous group of diseases are difficult to
diagnosis and there are currently no treatments. This
burden in pain and disability leads to poor quality of life
and high healthcare costs. Current research efforts are
focused on defining disease mechanisms and identifying
potential therapeutic targets. One emerging group of
GSDs are those resulting from defects in aggrecan,
which is the primary proteoglycan component of the
cartilage growth plate.
Review
Aggrecan-related bone disorders (ORPHA364817) including:
 spondyloepimetaphyseal dysplasia, aggrecan type
(ORPHA171866)
 macrocephally with multiple epiphyseal dysplasia
and distinctive facies (OMIN607131)
 spondyloepiphyseal dysplasia, Kimberley type
(ORPHA93283)
 familial osteochondritis dissecans (ORPHA251262)
 various idiopathic short stature phenotypes
Rare skeletal diseases can provide new insight
into fundamental disease mechanisms of cartilage
degradation
Osteoarthritis (OA) is the most common form of arth-
ritis. The World Health Organization estimates that
25 % of adults aged over 65 years suffer pain and/or dis-
ability from OA and it is ranked 12th for disease burden
in the EU25 with 35–40 million people in Europe suffering
from OA. OA is estimated to be 30–70 % genetic with
strong environmental risk factors of ageing, obesity and
joint trauma [1–3]. At the other end of the spectrum skel-
etal dysplasias are an extremely diverse and complex group
of rare diseases that affect the development and homeosta-
sis of the skeleton [4, 5]. There are more than 450 unique
and well-characterised phenotypes and although individu-
ally rare, as a group of related orphan diseases, they have
an overall prevalence of at least 1 per 4000 children. How-
ever, these genetically tractable skeletal dysplasias are a
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powerful tool for providing new insight into fundamental
disease mechanisms of generalised cartilage degradation
[6]. In this context, those skeletal dysplasias that result
from defects in cartilage structural proteins, such as the
collagens, proteoglycans and glycoproteins are of particular
relevance for identifying mechanisms of accelerated cartil-
age degradation that will provide new insight into more
common forms of OA [5, 6].
Introduction to aggrecan; structure and function
Aggrecan is a large chondroitin sulphated proteoglycan
and the founding member of the lectican protein family,
which also includes versican, brevican and neurocan [7].
It consists of a 250 kDa protein core with approximately
100 chondroitin sulphate glycosaminoglycan and 30 ker-
atan sulphate chains attached to a large domain located
between three globular domains. Aggrecan comprises an
N-terminal domain, two globular domains (G1 and G2),
two inter-globular domains, a selectin-like domain (G3)
and a C-terminal domain (Fig. 1) [7, 8]. The two inter-
globular domains act as chondroitin (CS) and keratin
(KS) sulphate attachment regions [8]. The large G3 do-
main contains two type II (epidermal growth factor-like)
repeats, a C-type lectin domain and a complement regu-
latory protein domain. Aggrecan is expressed in several
tissues including those in the brain, but is a major struc-
tural component of cartilage. The fixed negative charge
of this large proteoglycan is fundamental to cartilage be-
cause it attracts ions and water molecules, allowing the
cartilage to withstand the high mechanical load found in
the skeletal joint [7].
The disease relevance of aggrecan mutations
The fundamental importance of aggrecan for cartilage
development and homeostasis is well proven and was
originally illustrated by several naturally occurring muta-
tions such as the embryonically lethal chicken (nanomelia)
[9] and mouse (cmd) [10]. Furthermore, Dexter bulldog
dwarfism in cattle, which is a recessive form of dwarfism
documented since the 19th Century, has two causative
mutations in aggrecan [11]. More recently, genetic ana-
lysis of this most abundant of cartilage components is a
fast emerging area of human connective tissue research,
which will have a major influence on our understanding
of both rare and common cartilage diseases. In particular,
an allelic series of ACAN mutations have been identified
that result in a broad phenotypic spectrum including
spondyloepimetaphyseal dysplasia (SEMD) [12], spon-
dyloepiphyseal dysplasia Kimberley type (SED) [13],
familial osteochondritis dissecans [14] and various un-
defined short stature syndromes associated with accel-
erated bone maturation [15] (Table 1).
Clinical and radiographic description of the
human aggrecanopathies
Spondyloepiphyseal dysplasia, Kimberley type
(ORPHA93283; OMIM 608361)
A mild autosomal dominant condition in a single large
family characterised by proportionate short stature (<5th
percentile; males 141–162 cm and females 138–149 cm)
with a stocky appearance and severe progressive osteo-
arthritis of the large weight bearing joints requiring joint
replacement in middle age [16]. Radiographic features
Fig. 1 Schematic of the aggrecan showing the location of mutations and functions of the individual domains. Each of the seven human mutations is
indicated (top) in the relevant domains (middle) that each has a specific function (bottom). Key: ISS = idiopathic short stature; SED = spondyloepiphyseal
dysplasia; SEMD = spondyloepimetaphyseal dysplasia; OCD= osteochondritis dysplasia; G1 = globular domain 1; G2 = globular domain 2; G3 = globular
domain 3; KS = keratin sulphate attachment domain; CS = chondroitin sulphate attachment domain
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Table 1 Genetic and molecular findings in human aggrecanopathies and naturally occurring animal models
Gene mutation Exon Protein change Domain Molecular mechanism Phenotype Reference
c.272delA 3 Arg93Alafs*41 G1 Presumed haploinsufficiency Idiopathic short stature [15]
c.2026 + 1G > A 10 Not determined (but presumed exon skip) G2 1.Presumed truncated protein Idiopathic short stature [15]
2. Possible disruption to trafficking
c.3986dupC 12 Gly1330Trpfs*221 CS1 Presumed haploinsufficiency SED Kimberley type [13]
c.5391delG 12 Gly1797Glyfs*52 CS2 Presumed haploinsufficiency Dominant idiopathic short stature [22]
c.7064 T > C 14 Leu2355Pro G3 Presumed neomorphic Short stature, accelerated bone maturation,
and early growth cessation
[15]
c.6799G > A 15 Asp2267Asn G3 Presumed neomorphic Recessive SEMD, aggrecan type [12]
c.7249G > A 16 Val2303Met G3 Presumed neomorphic Dominant osteochondritis dissecans,
short stature, and early-onset osteoarthritis
[14, 17]
BD1 allele: 2266_2267insGGCA 11 Frame shift and introduction of PTC
in exon 11 (amino acid position 914)
1. Null due to NMD of mRNA from
mutant allele
Bulldog dwarfism (Dexter Cattle) [11]
Homozygous animals are embryonically lethal;
heterozygous animals have short-limbed
dwarfism with variable penetrance
2. Functional null due to production
of truncated protein
BD2 allele: −198C > T 1 Introduction of a novel start codon and
translation of a 91 amino acid peptide with
no resemblance to aggrecan; introduction
of a PTC
n/a
7 bp deletion leading to a
PTC in exon 6.
5 Reduced mRNA levels in cmd/cmd (41 %)
and cmd/wt (81 %) mice; truncated
aggrecan molecule
G1 Functional and/or transcriptional
null allele
Cmd (mouse) [24–29]
Homozygous mice are perinatally lethal;
heterozygous mice show age-related
spinal degeneration
Large deletion 2–18 Unknown G1-G3 Presumed null allele Cmd-bc (mouse) [30]
Homozygous mice are perinatally lethal
Glu1513Ter 10 Truncated aggrecan precursor that is
retained in the ER; reduced mRNA levels
CS2 Presumed null allele Nanomelia (chicken) [9, 27, 29, 31, 33]
Homozygous chicks are embryonically
lethal with shortened and malformed limbs
Unknown n/a Unknown Unknown Unknown CCI (rat) [35]
Homozygous rats have short-limbed dwarfism,
delayed anterior fontanel closing and
insufficient cartilage calcification
Details of the five aggrecan mutations that have been identified in families with a diverse range of human skeletal dysplasia and the naturally occurring animal models that have previously been studied
Key: NMD nonsense mediated degradation, PTC premature termination codon, G1 globular domain, G2 globular domain, CS chondroitin sulphate attachment domain, SED spondyloepiphyseal dysplasia,
SEMD spondyloepimetaphyseal dysplasia, BD bull dog dwarfism, cmd cartilage matrix deficiency allele/mouse, wt wild type allele
















were minor and included prominent end plate irregularity
and sclerosis of the vertebral bodies with mild and variable
epiphyseal changes associated with delayed bone age. SED
Kimberley results from a single-base pair insertion within
the variable repeat region of exon 12 (c.3986dupC) that
causes a frame shift of 212 amino acids and introduces a
premature stop codon (p.Gly1330Trpfs*221) [13].
Recessive spondyloepimetaphyseal dysplasia, aggrecan
type (ORPHA93283: OMIM 612813)
An autosomal recessive condition in a single family char-
acterised by extreme short stature (66–71 cm final height)
with short necks, barrel chests and mild lumbar lordosis
[12]. Craniofacial abnormalities include macrocephaly,
severe mid-face hypoplasia and slightly low set ears.
Radiographic examination showed irregular epiphyses
and widened metaphyses, particularly at the knees.
Spinal abnormalities included platyspondyly with mul-
tiple cervical-vertebral clefts, whilst in the hands there
was proportionate brachydactyly with accessory carpal
ossification centres. The carrier parents and half-sister in
this family had adult heights of approximately 150 cm,
whereas a non-carrier sister was 178 cm tall, suggesting
that heterozygous carriers may have a mild proportionate
short statue phenotype, similar to the familial osteochon-
dritis dissecans described by Stattin and colleagues [17] or
mild multiple epiphyseal dysplasia. SEMD, aggrecan type
results from homozygosity for p.Asp2267Asn in the G3
domain of aggrecan [12].
Macrocephaly with multiple epiphyseal dysplasia and
distinctive facies (OMIN607131; OMIM 607131)
An autosomal recessive disease identified in a large multi-
consanguineous family of Omani origin and clinically
characterised by normal height but with genu valgum and
dysmorphic features [18]. All four affected children had a
head circumference >90th centile and similar dysmorphic
features including macrocephaly, frontal bossing, hyperte-
lorism, a flat malar region and low set ears. Radiographs
showed generalised epiphyseal dysplasia, which was more
severe in the lower limbs. A second consanguineous
family of Turkish origin with clinical findings of macro-
cephaly and facial abnormalities, and radiographic fea-
tures of multiple epiphyseal dysplasia was reported by
Karaer and colleagues [19]. They suggested that this was a
second example of what they termed the “Al Gazali-
Bakalinova Syndrome”.
Genetic mapping of the Omani MMEDF family identi-
fied a homozygous linked region at 15q26.1, but excluded
aggrecan as a candidate gene due to heterozygosity for a
polymorphism in exon 6 of ACAN [20]. However, these
mapping data do not exclude the possibility of a recombin-
ation within ACAN, which might not be unexpected con-
sidering the large size of the gene (~75 kb). The genetic
basis of this disease remains unresolved, but it could
potentially be another member of the aggrecanopathies.
Autosomal dominant osteochondritis dissecans, short
stature, and early-onset osteoarthritis (ORPHA251262;
OMIM 165800)
Osteochondritis dissecans (OCD) is characterised by the
separation of an articular cartilage and subchondral bone
fragment from the articular surface. The fragmented tis-
sue may then become avascular and exist as a ‘loose
body’ within the joint space [21]. OCD is the most com-
mon cause of loose bodies in adolescent individuals and
has an approximate incidence of 1 in 2000 individuals.
The aetiology of generalised OCD is unknown, but is
likely to be a multifactorial combination of genetic variants,
ischaemia and/or repetitive trauma.
The 15 year old proband in a large autosomal domin-
ant family reported by Stattin and colleagues presented
initially at the age of 6 with pain in the knees after exercise
and a waddling gait [17]. Preliminary clinical examination
confirmed an unrecognised skeletal dysplasia characterised
by disproportionate short stature, low intervertebral discs
in the thoracic and lumbar spine and OCD in both knees
and a hip joint. A follow up analysis of the extended family
confirmed that affected members had OCD in at least one
joint and height ≤ −2 standard deviations when compared
to the control population [mean final height for affected
females was 148 cm (range 145–156) and for males was
156.5 cm (range 152–167)][17].
Idiopathic short stature
Several cases of idiopathic short stature with causative
mutations in aggrecan have recently been reported in
the United States [15, 22]. Four families presented with
autosomal dominant short stature, premature growth
cessation and accelerated bone age maturation. Affected
members of one family were heterozygous for a missense
mutation (c.7064 T > C; p.Leu2355Pro) in exon 14 en-
coding the C-type lectin of the G3 domain [15]. This
residue is highly conserved and the amino acid substitution
is predicted to disrupt the function of aggrecan, but this
has not been characterised in any detail. A second family
were found to have a frameshift mutation (c.5391delG) in
exon 12 (encoding the second inter-globular domain),
which is predicted to introduce a premature stop codon
(p.Gly1797Glyfs*52) [22]. Similarly, a third family were
found to have a frameshift mutation (c.272delA) in exon 3
(encoding the G1 domain) that is predicted to produce a
truncated protein (p.Arg93Alafs*41) [15]. Finally, a fourth
family were found to have a novel base-pair substitution
(c.2026 + 1G >A) in the highly conserved splice donor site
of exon 10, which is predicted to result in incorrect splicing
and the skipping of exon 10 [17]. The effect of this muta-
tion on mRNA splicing was not investigated further, but
Gibson and Briggs Orphanet Journal of Rare Diseases  (2016) 11:86 Page 4 of 8
might result in an in-frame deletion of 97 amino acids
from the G2 domain of aggrecan.
Aetiology and disease mechanisms in human
aggrecanopathies
The 2015 revision of the “Nosology and Classification of
Genetic Skeletal Disorders” provides a comprehensive
catalogue of over 400 genetic disorders of the skeleton in
42 individual groups. The approach taken for the grouping
of disorders was a combination of 1) a single gene or
group of related genes 2) specific phenotypic feature, or 3)
by radiological description. The aggrecanopathies are
placed in a single group (number 6) based on genetic cri-
teria alone. Recently, we have reviewed a select range of
genetic skeletal diseases and have suggested alternative
groupings based on common disease mechanisms. We
now propose that there are potentially two different
disease mechanisms in the aggrecan disease spectrum
that are focused on either quantitative or qualitative de-
fects [4, 5].
Premature termination codons potentially resulting in
truncated proteins or haploinsufficiency through
nonsense mediated mRNA degradation
The heterozygous mutations identified in SED Kimberley
(p.Gly1330Trpfs*221) [13] and some idiopathic short stat-
ure phenotypes (p.Gly1797Glyfs*52 and p.Arg93Alafs*41)
[15] are predicted to cause a frame shift that introduces a
premature termination codon. Premature termination co-
dons usually result in nonsense-mediated degradation
(NMD) of mRNA from the mutant allele [23] and there-
fore presumed haploinsufficiency for aggrecan. Unfortu-
nately, cartilage mRNA was not available from any of
these patients and it has not been possible to determine
whether these human mutations cause NMD or allow
translation of a truncated aggrecan protein that might be
secreted into the cartilage extracellular matrix or retained
and/or degraded. Retention and/or secretion into the
ECM of a truncated aggrecan protein could possibly exert
a dominant negative effect on cartilage structure and/or
function.
Dominant-negative (neo-morphic) missense mutations
that disrupt cartilage structure and function
Interestingly, all three ACAN missense mutations,
Leu2355Pro [15], Asp2267Asn and [12] Val2303Met
[14] are located within the G3-domain (C-type lectin)
and yet result in phenotypes that define the extensive
clinical spectrum of the aggrecanopathies. For example,
Asp2267Asn results in severe recessive SEMD charac-
terised by extreme short stature (final adult height of
only 66–71 cm) [12]; in contrast, patients with Val2303-
Met and Leu2355Pro present with milder phenotypes
characterised by dominantly inherited osteochondritis
dissecans (with mild short stature) [14] or short stature
with accelerated bone maturation respectively [15].
It would therefore seem logical that this dichotomy in
clinical severity is due to profoundly different disease
mechanisms, and yet, biochemical analysis has revealed
similar but modest pathological variances in vitro. For
example, previous studies used patient cartilage and sur-
rogate cell models to study the functional consequences
of Asp2267Asn and Val2303Met [12, 14]. Both muta-
tions allowed the secretion of mutant recombinant
aggrecan G3-domains, but disrupted binding to several
interacting partners such as fibulin-1 & -2 (Val2303Met)
[14] and tenascin-R (Val2303Met) [14] or tenascin-C
(Asp2267Asn) [12]. Neither of these biochemical studies
therefore provided a mechanistic link between the specific
aggrecan missense mutations and the resulting disease
phenotypes of either severe short stature or cartilage in-
stability. However, the apparent secretion of mutant
aggrecan protein in vitro suggests that changes to the
cartilage ECM are likely to be the underlying cause of
disease pathology. These mutations will therefore pro-
vide a unique opportunity to study the role of abnormal
cartilage ECM in disease initiation and progression, and
how this pathology might relate to changes in cell pheno-
type. Unfortunately, the only well-characterised in vivo
models previously studied are either the mouse cmd
(cartilage matrix deficiency) [24–29] or the chick nano-
melia, both of which are lethal and therefore of limited
value for studying disease mechanisms in human aggre-
canopathies. In the long term an allelic series of aggre-
can transgenic mouse models will provide a valuable
and unique resource to determine in vivo how
spatially-related mutations can cause either profound
disruptions to the cartilage growth plate and severely
reduced bone growth (i.e. SEMD) or generalised cartil-
age instability that leads to osteochondritis dissecans.
Existing animal models for studying disease
mechanisms in aggrecanopathies
The only in vivo models of aggrecan pathologies previously
studied are either the mouse cmd/cmd-bc (cartilage matrix
deficiency) or the chick nanomelia, both of which are
lethal as homozygotes and therefore of limited value as
disease models for studying human aggrecanopathies
(Table 1). In contrast, the heterozygote forms of these
disorders are non-lethal and are therefore potentially
useful as models; indeed, the biochemical analysis of
tissues from all of these models has provided valuable
insight into the role of aggrecan in cartilage develop-
ment and homeostasis (Table 1).
Cartilage matrix deficiency mouse (cmd)
The cmd mouse is the best studied of the aggrecan ani-
mal models [24–29] and results from a 7 bp deletion in
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exon 5 [27] that arose on an agouti background and is
homozygous perinatal lethal. Mutant pups have abnor-
mal tracheal cartilage and so respiratory failure occurs
soon after birth. Other phenotypic features include dis-
proportionate dwarfism, enlarged abdomen, short snout
and tail, cleft palate and a protruding tongue. Studies
have shown that the growth plate of these animals is dis-
organised and irregular; for example, there is a reduction
in hypertrophic chondrocytes and the zones are no longer
clearly defined with abnormal numbers of collagen fibrils
[25, 29]. Aggrecan mRNA levels are reduced to 81 % and
the expression patterns of other extracellular matrix mole-
cules such as link protein, syndecan-3 and collagen II are
all altered [28]. Interestingly, heterozygote mice are ini-
tially phenotypically normal, but develop proportional
dwarfism by 28 days with age-associated spinal disc de-
generation. The growth plates are irregular and there is a
reduction in aggrecan mRNA levels to 41 % [20]. Cervical
lordosis and thoraco-lumbar kyphosis develop and even-
tually lead to spinal misalignment. A primary lesion oc-
curs in the intervertebral discs and there is decreased
movement, which is often due to spastic paralysis in
the hind limbs [20]. The mutant mice usually die within
19 months from starvation.
The related Cmd-bc mutation [30] spontaneously
arose on a BALB/c GaBc background and, similar to the
Cmd mouse, is perinatally lethal in homozygotes (the
heterozygote has not been studied to date). Mutant pups
have short-limbed dwarfism, an enlarged abdomen, pro-
truding tongue, cleft palate and shortened snout. Although
this phenotype is also due to a deletion, it arose through a
non-homologous recombination event and so is far more
extensive than Cmd causing the loss of exons 2–18 [30].
The nanomelia chick model
The nanomelia chick is an autosomal recessive and em-
bryonically lethal mutation [9]. Affected chick embryos
display short-limbed dwarfism with a range of skeletal
abnormalities. These irregularities include a large, bra-
chycephalic head and an abnormal mandible and maxilla
(causing a parrot-like beak) [9]. Further investigation re-
vealed a transition (c.G4553T) that introduces a stop
codon, premature termination and a truncated aggrecan
precursor [31, 32], which is retained in the endoplasmic
reticulum and does not undergo processing to mature
aggrecan [33].
Dexter bulldog dwarfism (Dexter cattle)
Dexter bulldog dwarfism is one of the oldest recorded
naturally occurring animal genetic disorders and is fatal,
resulting in the spontaneous mid to late-term abortion
of homozygotes [34]. Homozygote calves display severe
short-limbed dwarfism with a short vertebral column,
marked vertebral platyspondyly, large abdominal hernia
and extreme rib shortening. The head is disproportion-
ately large with several abnormalities including midfacial
retraction, relative prognathism, retruded muzzle and cleft
palate. Heterozygote animals exhibit milder disproportion-
ate dwarfism with rhizomelia, mild vertebral body irregu-
larity and posterior wedging of vertebrae [34]. There are
two causative mutations; a 4 bp insertion in exon 11 that
causes a frameshift and premature stop codon (BD1) and
a transition in exon 1 that introduces a novel ATG start
codon and a large frameshift (BD2) [11]. The putative mu-
tant protein resulting from the BD2 mutation therefore
has no resemblance to normal aggrecan. An in-depth ana-
lysis of Dexter bulldog dwarfism (BD1) has confirmed
nonsense-mediated mRNA degradation from the mutant
allele [11].
Cartilage Calcification Insufficient rats (CCI)
The CCI rat mutation arose spontaneously in a Jcl-
derived Sprague–Dawley colony [35]. The genetic cause
of this rodent phenotype is currently unknown but it is
thought to be an aggrecan synthesis disorder, inherited in
an autosomal recessive manner. Mutant rats have short-
limbed dwarfism with a short vertebral column and tail.
The skull length is reduced with a delay in anterior fonta-
nel closing. The bone spicules appear thicker and ran-
domly organised, whilst the growth plate is irregular with
a poorly formed secondary ossification centre and delayed
endochondral ossification. Aggrecan expression in both
articular cartilage and the growth plate is abnormal [35].
Conclusions and future directions
Although the first human aggrecan mutation was genet-
ically mapped in 2002 [36] and then molecularly defined
in 2005 [13], remarkably, only six additional mutations
have been identified and published in the intervening
10 years (Table 1). This limited identification of new mu-
tations is most likely due to the difficulties in sequencing
the relatively large and repetitive (i.e. intragenic VNTR)
aggrecan gene using traditional Sanger approaches and a
lack of multi-generation families for linkage studies. How-
ever, the adoption of next generation sequencing in both
research and clinical diagnostics is starting to identify a
plethora of ACAN variants of known and unknown func-
tional relevance. The challenge now is to understand the
functional significance of these novel variants, in particu-
lar missense mutations, and to determine disease mecha-
nisms for the subsequent identification of therapeutic
targets.
The study of specific human aggrecan variants has
previously relied on surrogate cell model systems and a
limited number of cartilage samples [12, 14], whilst the
various naturally occurring animal models are not neces-
sarily relevant for the equivalent human disease. How-
ever, recent research and technological initiatives and
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advances will help to readdress this imbalance. For ex-
ample, the European Commission FP7-Heath funded
project SYBIL (systems biology for the functional valid-
ation of genetic determinants of skeletal diseases) is cur-
rently generating and deep-phenotyping two mouse
models of the aggrecanopathies that will ultimately help
to determine disease mechanisms, whilst the use of genome
editing will allow additional cell and mouse models to be
generated and phenotyped in-depth as new variants of un-
known significance are identified.
Defining disease mechanisms and identifying new thera-
peutic targets in the aggrecanopthies is likely to present a
challenge, but it is tempting to speculate that they may fall
into two broad categories focused on either quantitative
or qualitative mechanisms. For the latter group, through
studying a broad range of different genetic skeletal phe-
notypes resulting from dominant-negative (neo/anti-
morphic) mutations in cartilage structural proteins, ER
stress has been identified as a common disease mechanism
[6]. Moreover, targeting ER stress as a therapeutic route by
pharmacological agents is an exciting proposition that is
gaining ever-greater momentum.
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